These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 27258669

  • 1. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
    Azuma K, Obata R, Nomura Y, Tan X, Takahashi H, Yanagi Y.
    Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669
    [Abstract] [Full Text] [Related]

  • 2. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M, Kano M, Itagaki K, Ise S, Imaizumi K, Sekiryu T.
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [Abstract] [Full Text] [Related]

  • 3. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ, Kim KM, Kim HS, Han JI, Kim CG, Lee TG, Kim JW.
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [Abstract] [Full Text] [Related]

  • 4. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Hara C, Sawa M, Sayanagi K, Nishida K.
    Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
    [Abstract] [Full Text] [Related]

  • 5. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T.
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [Abstract] [Full Text] [Related]

  • 6. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M, Shiraga F, Yamashita A, Shiragami C, Ono A, Shirakata Y, Kimura S, Shiode Y, Kawata T, Hosogi M, Fujiwara A, Morizane Y.
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [Abstract] [Full Text] [Related]

  • 7. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
    Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T.
    Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
    [Abstract] [Full Text] [Related]

  • 8. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
    Ijiri S, Sugiyama K.
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y, Iwahashi C, Gomi F.
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [Abstract] [Full Text] [Related]

  • 10. Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks.
    Sekfali R, Mimoun G, Cohen SY, Querques G, Bandello F, Sacconi R, Souied EH, Capuano V.
    Eur J Ophthalmol; 2020 May; 30(3):550-556. PubMed ID: 30880436
    [Abstract] [Full Text] [Related]

  • 11. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
    Inoue M, Yamane S, Taoka R, Arakawa A, Kadonosono K.
    Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
    [Abstract] [Full Text] [Related]

  • 12. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
    Lee JH, Lee WK.
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
    [Abstract] [Full Text] [Related]

  • 13. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [Abstract] [Full Text] [Related]

  • 14. Visual Prognosis in the Better-seeing Eyes of Patients with Unilateral Polypoidal Choroidal Vasculopathy.
    Kim JH, Kim JW, Kim CG, Lee DW.
    Optom Vis Sci; 2019 Sep; 96(9):686-694. PubMed ID: 31479024
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, Yoshikawa M, Takahashi A, Yoshimura N.
    Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1471-7. PubMed ID: 25391986
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T, Okano K, Kohno H, Tsuneoka H.
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [Abstract] [Full Text] [Related]

  • 20. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K, Uematsu S, Hara C, Wakabayashi T, Fukushima Y, Sato S, Ikuno Y, Nishida K.
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.